Table 2.
Immunogenicity of the first dose of the COVID-19 vaccine BNT162b2
|
Anti-SARS-CoV-2 IgG (serological) vaccine response |
T-cell vaccine response |
||||
|---|---|---|---|---|---|
| Number of responders | Proportion of responders (95% CI) | Number of responders | Proportion of responders (95% CI) | ||
| Healthy controls | 17/17 | 100% (80–100) | 11/16 | 69% (41–89) | |
| Patients on immunosuppressants | 60/77 | 78% (67–87) | 65/77 | 84% (74–92) | |
| Patients on methotrexate | 7/15 | 47% (21–73) | 14/15 | 93% (68–100) | |
| Patients on TNF inhibitors | 19/24 | 79% (58–93) | 19/24 | 79% (58–93) | |
| Patients on IL-17 inhibitors | 15/15 | 100% (78–100) | 14/15 | 93% (68–100) | |
| Patients on IL-23 inhibitors | 19/23 | 83% (61–95) | 18/23 | 78% (56–93) | |
A threshold EC50 value of 25 was used for anti-SARS-CoV-2 IgG titres, at which serological responses were classified as positive. A threshold value of 30 cytokine-secreting cells per million peripheral blood mononuclear cells was established for total T-cell responses (interferon-γ, IL-2, or IL-21), at which the T-cell response was classified as positive. EC50=half maximal effective concentration. Humoral and cellular data were missing for two patients on methotrexate, three patients on TNF inhibitors, and two patients on IL-23 inhibitors. No cellular data were available for one healthy control. IL=interleukin. TNF=tumour necrosis factor.